Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors

Колонтарев, К. Б.; Govorov, Alexander; Kasyan, George; Priymak, Diana; Pushkar, Dmitry

doi:10.5173/ceju.2016.879

Cited by 4 publications

(1 citation statement)

References 35 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contents lists available at SciOpen journal homepage: https://www.sciopen.com/journal/2097-0765 Publishing services by Tsinghua University Press society ages [3] . Approved medical therapies for BPH are limited to alpha-blockers, 5-alpha reductase inhibitors, and phosphodiesterase type 5 inhibitors [4] .…”

Section: Food Science and Human Wellnessmentioning

confidence: 99%

Alleviatory effect of isoquercetin on benign prostatic hyperplasia via IGF-1/PI3K/Akt/mTOR pathway

Choi,

Fan,

Wedamulla

et al. 2024

Food Science and Human Wellness

View full text Add to dashboard Cite

We evaluated the effect of isoquercetin (quercetin-O-3-glucoside-quercetin, IQ) as a functional component of Abeliophyllum disistichum Nakai ethanol extract (ADLE) on prostate cell proliferation and apoptosis and its effects on the IGF-1/PI3K/Akt/mTOR pathway in benign prostatic hyperplasia (BPH). Metabolites in ADLE were analyzed using UHPLC-qTOF-MS and HPLC. IQ was orally administered (1 or 10 mg/kg) to a testosterone propionate-induced BPH rat model, and its effects on the prostate weight were evaluated. The effect of IQ on androgen receptor (AR) signaling was analyzed in LNCaP cells. Whether IGF-1 and IQ affect the IGF-1/PI3K/Akt/mTOR pathway in BPH-1 cells was also examined. The metabolites in ADLE were identifi ed and quantifi ed, which confi rmed that ADLE contained abundant IQ (20.88 mg/g). IQ signifi cantly reduced the prostate size in a concentration-dependent manner in a BPH rat model, and signifi cantly decreased the expression of AR signaling factors in the rat prostate tissue and LNCaP cells in a concentration-dependent manner. IQ also inhibited the PI3K/AKT/mTOR pathway activated by IGF-1 treatment in BPH-1 cells. In BPH-1 cells, IQ led to G0/G1 arrest and suppressed the expression of proliferation factors while inducing apoptosis. Thus, IQ shows potential for use as a pharmaceutical and nutraceutical for BPH.

show abstract

Section: Food Science and Human Wellnessmentioning

confidence: 99%

Alleviatory effect of isoquercetin on benign prostatic hyperplasia via IGF-1/PI3K/Akt/mTOR pathway

Choi,

Fan,

Wedamulla

et al. 2024

Food Science and Human Wellness

View full text Add to dashboard Cite

show abstract

Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis

Zhang

Yang

et al. 2018

World J Urol

View full text Add to dashboard Cite

show abstract

Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled, randomized clinical trial

Pushkar

Винаров

Spivak

et al. 2018

Cent european J Urol

View full text Add to dashboard Cite

IntroductionIn order to investigate the efficacy and safety of Afalaza in men with benign prostatic hyperplasia (BPH) at risk of progression, this multicenter, double-blind, placebo-controlled, randomized clinical trial was performed. Derived by technological treatment of antibodies to prostate-specific antigen (PSA) and endothelial nitric oxide synthase (eNOs), Afalaza was previously proved to modulate its molecular targets. The mechanism of action of the drug is associated with the modulating effect of the antibiodies (RA-Abs) on the molecular targets (PSA and eNOS) by way of conformational changes.Material and methodsA total of 249 patients aged 45–60 years with BPH and moderate lower urinary tract symptoms (LUTS), total prostate volume (TPV) ≥30 cm3, Qmax 10–15 ml/s, and serum PSA<4 ng/ml were randomly assigned to receive either Afalaza (n = 125) or placebo (n = 124) for 12 months. Changes in BPH/LUTS symptoms (according to the International Prostate Symptom Score), Qmax, TPV, PSA, BPH clinical progression, occurrence of acure urinary retention (AUR) events or BPH-related surgery were estimated as the study endpoints.ResultsIPSS mean change was -3.7 ±3.0 (95% CI -4.3 to -3.2) after 12 months of Afalaza (vs. -2.9 ±2.4; 95% CI -3.3 to -2.4 in placebo; р = 0.02). Qmax growth was 2.5 ±4.3 ml/s (vs. 1.4 ±3.3 in placebo; p = 0.049), TPV reduced by 11.8 ±16.0% (vs. 6.5 ±14.7%; p = 0.01, and PSA remained unchanged. Afalaza therapy resulted in a significant decrease in the total sum of BPH progression symptoms (p = 0.01). The maximum effect of Afalaza was registered after 12 months without a tendency to form a ‘plateau’. During the study, no patients experienced AUR or BPH-related surgery.ConclusionsA 12-month course of Afalaza therapy is effective and safe for patients with BPH. The results of end points measurements revealed asignificant advantage of Afalaza compared to placebo in the overall symptoms benefit and a decline in the risk of BPH progression.ClinicalTrials.gov: NCT01716104.

show abstract

Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors

Cited by 4 publications

References 35 publications

Alleviatory effect of isoquercetin on benign prostatic hyperplasia via IGF-1/PI3K/Akt/mTOR pathway

Alleviatory effect of isoquercetin on benign prostatic hyperplasia via IGF-1/PI3K/Akt/mTOR pathway

Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis

Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled, randomized clinical trial

Contact Info

Product

Resources

About